The Hawaii Parkinson’s & Movement Center and Hawaii Parkinson’s Research Unit have been awarded Hawaiʻi’s first clinical research study focused on Lewy Body Dementia (LBD). This landmark study investigates ACP-204 (remlifanserin), an investigational medication developed to treat hallucinations and delusions…
Researchers at the Hawaii Parkinson’s Disease Center and Hawaii Parkinson’s Research Unit are participating in groundbreaking research evaluating prasinezumab, an investigational monoclonal antibody that may become the first disease-modifying treatment to slow the progression of Parkinson’s disease. This research is…
Accurate detection of mild cognitive impairment (MCI) and Alzheimer’s disease (AD) is critical as therapeutic strategies increasingly emphasize early intervention. While the Mini-Mental State Examination (MMSE) remains a widely used cognitive screening tool, its sensitivity to subtle neurophysiological changes is…
Early and accurate differentiation between Alzheimer’s disease (AD) and mild cognitive impairment (MCI) is increasingly critical as new disease-modifying therapies emphasize intervention at the earliest possible stages. However, MCI often represents a heterogeneous and nonspecific prodromal phase, complicating clinical diagnosis…
The Hawaii Headache & Facial Pain Center and Hawaii Headache Research Unit have been awarded a clinical research study to investigate XEOMIN® (incobotulinumtoxinA) as a potential preventive treatment for chronic and episodic migraine. This important research initiative aims to address…
The American Academy of Neurology (AAN) official continuing medical education journal, Continuum: Lifelong Learning in Neurology®, has referenced research conducted by University of Hawaiʻi John A. Burns School of Medicine (JABSOM) neurologists and former medical students in its June 2025…
The American Academy of Neurology (AAN) official continuing medical education journal, Continuum: Lifelong Learning in Neurology®, has referenced research conducted by University of Hawaiʻi John A. Burns School of Medicine (JABSOM) neurologists and former medical students in its February 2025…
ERP Biomarkers of Cognitive Dysfunction in Alzheimer’s Disease: Real-World Evidence Supporting Translational Clinical Trial Endpoints Advances in neuroscience and digital biomarkers are transforming how clinicians and researchers detect, monitor, and study Alzheimer’s disease (AD). At the 2025 Clinical Trials on…
The Hawaii ALS and Neuromuscular Center has been selected to participate in the ADAPT-EARLY clinical trial, a Phase 4 research study evaluating efgartigimod PH20 SC in adults with new-onset generalized myasthenia gravis (gMG). This important study focuses on early treatment…
Brainshuttle™ Launched in Hawaii! Novel Alzheimer’s Drug Trontinemab with Brainshuttle™ Technology A new Alzheimer’s clinical study using the investigational drug trontinemab, engineered with Brainshuttle™ technology, is now accepting participants in Hawaii. This approach aims to achieve rapid amyloid clearance with…
RECENT BLOGS
-
Hawaii Selected to Investigate Povetacicept for Myasthenia Gravis
-
Assessing the Understanding of Neurological Conditions in Young Adults and Leveraging Media Outlets and Social Media Platforms for Neurology Awareness
-
Hawaii’s First Clinical Trial Investigates Preventive Treatment for Menstrual Migraine
-
Predictors of Depressive Symptoms in Post-Concussion Syndrome
-
Utilizing ZIP Code-Based Choropleth Maps to Improve Equity in Alzheimer’s Clinical Trial Recruitment in Hawai‘i
-
Debunking Myths and Misinformation About Alzheimer’s Disease
-
'Knowledge is power:'Healthy brain habits w/Dr. Kore Liow | Unscripted
-
Predictors of Depressive Symptoms in Post-Concussion Syndrome
HPN Office Hours
Monday :
8AM - 5PM
Tuesday :
8AM - 5PM
Wednesday :
8AM - 5PM
Thursday :
8AM - 5PM
Friday :
8AM - 5PM
Saturday :
CLOSED
SUNDAY :
CLOSED